XML Financial LLC Lowers Position in Amgen Inc. $AMGN

XML Financial LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,980 shares of the medical research company’s stock after selling 2,163 shares during the quarter. XML Financial LLC’s holdings in Amgen were worth $6,540,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Anfield Capital Management LLC grew its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the 4th quarter worth $26,000. Manning & Napier Advisors LLC grew its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new position in shares of Amgen during the 4th quarter worth $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Stock Performance

Shares of Amgen stock opened at $349.58 on Friday. The business has a 50-day moving average of $341.35 and a 200 day moving average of $345.47. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The stock has a market capitalization of $188.67 billion, a price-to-earnings ratio of 24.33, a price-to-earnings-growth ratio of 3.51 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the business posted $4.90 EPS. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AMGN. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Truist Financial raised their price target on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Barclays assumed coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Canaccord Genuity Group assumed coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Finally, Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $353.81.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.